Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
Drug Approval

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ

  • By IPP Bureau | October 07, 2025

Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg.

Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism.

ZDS - Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International